Guggenheim Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $70
Rhythm Pharmaceuticals Is Maintained at Neutral by B of A Securities
Rhythm Pharmaceuticals Analyst Ratings
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Raises Target Price to $52
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $55
Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $53
Wells Fargo Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $64
H.C. Wainwright Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $64
Rhythm Pharmaceuticals Price Target Announced at $64.00/Share by JMP Securities
Rhythm Pharmaceuticals Analyst Ratings
JMP Securities Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $64
Wells Fargo Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Morgan Stanley Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $55 Price Target
Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Strong Imcivree Sales and Promising Clinical Trials
Stifel Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $64
Stifel Nicolaus Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Needham Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $55